 OUTLINE: This is a randomized, multicenter study. Patients are stratified according to concurrent chemotherapy or radiotherapy yes vs no, concurrent platinum-based cisplatin or carboplatin chemotherapy yes vs no, degree of anemia mild hemoglobin at least 9.0 gdL vs severe hemoglobin less than 9.0 gdL, age 60 and under vs over 60, and type of neoplasm plasma cell disorder including multiple myeloma or lymphoproliferative disorder including non-Hodgkins lymphoma and chronic lymphocytic leukemia vs all other neoplasms. 